Current Advances in Endovascular Treatment of Intracranial Atherosclerotic Disease and Future Prospective

Intracranial atherosclerotic disease (ICAD) is an important cause of large vessel disease leading to acute ischemic stroke (AIS). Currently, medical management such as risk factor control, antiplatelet therapy, and lifestyle changes are considered the first-line of treatment to prevent transient ischemic attack (TIA) or AIS.1 The results of the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial2 demonstrated that symptomatic ICAD is a high-risk cause of recurrent stroke and highlighted the need for better treatment strategies, leading to consideration for both better medical management and the possibility of angioplasty and stenting.

Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2020 Category: Neurology Authors: Mostafa Jafari, Thanh N. Nguyen, Santiago Ortega-Gutierrez, Muhammad Shazam Hussain, Ameer E. Hassan, Asad Ikram, Javed Khader Eliyas, Gustavo J. Rodriguez, Afshin A. Divani Tags: Review Article Source Type: research